Cheol Young Maeng

Title: Cheol Young Maeng: Innovator in Pharmaceutical Research from Daejeon, KR

Introduction

Cheol Young Maeng is a noteworthy inventor based in Daejeon, South Korea, recognized for his significant contributions to pharmaceutical innovations. With a total of 9 patents to his name, he is at the forefront of developing compounds that promise to enhance therapeutic interventions.

Latest Patents

One of his latest patents focuses on an imidazopyrimidine and imidazotriazine derivative, alongside a pharmaceutical composition comprising these compounds. The invention highlights a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, which acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5). This groundbreaking work is particularly beneficial for the prevention or treatment of disorders mediated by glutamate dysfunction and the mGluR5 receptor.

Career Highlights

Cheol Young Maeng has made substantial strides in the pharmaceutical sector while working at SK Biopharmaceuticals Co., Ltd. His research focuses on identifying modulators that can potentially transform the understanding and treatment of various neurological disorders, reflecting a commitment to innovation in healthcare.

Collaborations

Throughout his career, Maeng has collaborated with notable coworkers such as Young Koo Jang and Chan Mi Joung. Their collective expertise fosters an environment of innovation, essential for advancing the field of pharmaceutical sciences and improving patient outcomes.

Conclusion

Cheol Young Maeng exemplifies the spirit of innovation within the pharmaceutical industry. His contributions through patented inventions underscore the importance of research and collaboration in creating new therapies that address significant health challenges. His work holds promise for the future of medicine and the treatment of disorders related to glutamate dysfunction.